-
Aug 4, 2023 | 
cancernetwork.com | Al-Ola Abdallah |Leyla O. Shune |Nausheen Ahmed |Jordan Snyder
Transcript:Al-Ola Abdallah, MD: Jordan, this is a case we’re commonly seeing that’s unfortunately common. We have to talk about the issue of infection rate, which is very high with [the use of] bispecifics. We’re going to use them more, and we’re not talking about just as a single agent. This is a single agent, by the way. But in combination therapy we’re going to see more than that. With daratumumab there’s an increased risk for infection.
-
Jul 28, 2023 | 
cancernetwork.com | Al-Ola Abdallah |Leyla O. Shune |Nausheen Ahmed |Jordan Snyder
Transcript:Al-Ola Abdallah, MD: Nausheen, many BCMA BiTES [bispecific T-cell engagers] are coming out, and there are other targeted therapies that Dr Leyla [Shune] told us about. Can you talk about some of these drugs, like talquetamab and cevostamab? Nausheen Ahmed, MD: These are promising therapies coming out. Once we start using these BCMA therapies and seeing resistance to BCMA-directed therapies, then these are other targets.
-
Jul 28, 2023 | 
cancernetwork.com | Al-Ola Abdallah |Leyla O. Shune |Nausheen Ahmed |Jordan Snyder
Transcript:Al-Ola Abdallah, MD: Jordan, going back to you, after CAR [chimeric antigen receptor] T-cell therapy failure, we don’t have any really [good] options. Teclistamab got FDA approved at that time, we decided that she was actually our first patient that we admitted her. I gave her teclistamab. I remember when I came before the third dose, she would tell me that the mass she felt is actually trending down. I [was] holding my breath with the PET scan, making sure it’s actually going down.
-
Jul 21, 2023 | 
cancernetwork.com | Al-Ola Abdallah |Leyla O. Shune |Nausheen Ahmed |Jordan Snyder
Transcript:Al-Ola Abdallah, MD: Leyla…for this case that we saw a lot of relapses. My question here is that for the CAR [chimeric antigen receptor] T-cell therapy, I think this was used appropriately waiting for the triple refractory. CAR T was approved here after patients actually progress on daratumumab, we don’t really have a standard of care. That’s a reality. We just assume that these are the options.
-
Jul 21, 2023 | 
cancernetwork.com | Al-Ola Abdallah |Leyla O. Shune |Nausheen Ahmed |Jordan Snyder
Transcript:Al-Ola Abdallah, MD: Moving forward, we’ll talk about case 3. I think this case is more [interesting] because we’re going to have to discuss further about many new treatments. This is a 73-year-old female patient diagnosed with myeloma in 2019. [She was] complaining of back pain. The imaging study initially showed a T7 fracture. This patient got induction therapy already. She was eligible for transplant, but she opted not to do transplant. This is something I think we see in some patients.
-
Jul 14, 2023 | 
cancernetwork.com | Al-Ola Abdallah |Leyla O. Shune |Nausheen Ahmed |Jordan Snyder
Transcript:Nausheen Ahmed, MD: Dr Abdallah, what are your thoughts about VRd [bortezomib-lenalidomide-dexamethasone] vs DRd [daratumumab-lenalidomide-dexamethasone] based on the first of the SWOG study and comparing that to the MAIA trial? Al-Ola Abdallah, MD: I think, as Leyla said, we have to look at different aspects. I think the problem here is that before the overall survival [OS] benefit, we saw it. I was still saying the VRd is supposed to be the standard here.
-
Jul 14, 2023 | 
cancernetwork.com | Al-Ola Abdallah |Leyla O. Shune |Nausheen Ahmed |Jordan Snyder
Transcript:Al-Ola Abdallah, MD: Nausheen, we’re not going to go to the other case without talking about CAR [chimeric antigen receptor] T-cell [therapy] for transplant. I think this is something we are seeing some trials on. Any thoughts about that? We’re not talking about transplant. We’re talking about the daratumumab-Revlimid [lenalidomide]-dexamethasone, especially some newer trials that we’re going to talk about that later on [with] the efficacy of the CAR T-cell and the safety.
-
Jul 7, 2023 | 
cancernetwork.com | Al-Ola Abdallah |Leyla O. Shune |Nausheen Ahmed |Jordan Snyder
Transcript:Al-Ola Abdallah, MD: We have to put this into consideration that we have several trials for transplant-ineligible patients. I know there’s [debate] about these patients. Some of them are fit for transplant, so why didn’t we do that? But the MAIA trial may be a successful example of a randomized trial that they compare daratumumab-lenalidomide-dexamethasone with the previously known lenalidomide-dexamethasone that was the standard of care.
-
Jul 7, 2023 | 
cancernetwork.com | Al-Ola Abdallah |Leyla O. Shune |Nausheen Ahmed |Jordan Snyder
Transcript:Al-Ola Abdallah, MD: We’re moving to the next case. A newly diagnosed myeloma 79-year-old male patient with a known history of aortic valve insufficiency, coronary artery disease, dyslipidemia, and diabetes mellitus type-2. He’s complaining of generalized fatigue, went to his primary care physician, found out his WBC [white blood cell] was 4.7. Hemoglobin was low- 7.275 [g/dL]. His kidneys’ creatinine was elevated at 2.4 [mg/dL]. He was known to have a baseline of creatinine 1.3 [mg/dL].
-
Jul 4, 2023 | 
cancernetwork.com | Al-Ola Abdallah |Nausheen Ahmed |Leyla O. Shune |Jordan Snyder
Jul 4, 2023The standard of care for high-risk multiple myeloma remains unsettled, according to an expert panel from Kansas City. A panel of experts tackled a complex patient case at a recent Around the Practice® program hosted by CancerNetwork®. During the discussion, panelists also touched on various recent trials in this space and discussed current practices in the care of this disease. The panel was led by Al-Ola A.
